As a popular role in the era of precision medicine, ICIs still need one or a set of clear efficacy prediction indicators to promote their clinical application, while the expression level of tumor PD-L1 still cannot be the absolute standard of immunotherapy guidance. The gene discussed is CD274; the disease is neoplasm.